glp 1 receptor agonists for type 2 diabetes GLP-1 are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 Receptor Agonists and Research

Given the pilot nature of the trial, the (relatively) small degree of weight loss achieved, and the well-described association between weight loss and fracture risk, we believe that further exploration into this increasingly relevant question is warranted

Listen Labs' AI interviews reveal surprising trends, using real data to show consumer goods companies how they can adapt

TRIUMPH-OUTCOMES (NCT06383390) will investigate the impact of retatrutide vs

A patch that delivers only 1030% of the dose needed creates a subtherapeutic effect, leaving patients hungry and without the metabolic benefits of higher doses

doi: 10.1016/j.jcjd.2019.09.003 110 HusainMBirkenfeldALDonsmarkMDunganKEliaschewitzFGFrancoDRet al

These variables, which were selected because they are likely to affect treatment outcomes, encompassed both demographic factors (region, sex, age at index date) and clinical history (baseline HbA1c, baseline weight, CVD in the past 365 day [coronary heart disease, cerebrovascular disease, peripheral vascular disease or heart failure], CharlsonDeyo risk index score), as well as index year, insurance type and previous receipt of oral antidiabetic medications